Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Denileukin diftitox + Temsirolimus |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Denileukin diftitox | Ontak | DAB389IL2|DAB389-IL2|LY335348|DAB389 interleukin-2 | Ontak (denileukin diftitox) is an interleukin-2 (IL-2) recombinant fusion protein comprised of the IL-2 protein and the diptheria toxin, and may potentially inhibit the growth and survival of tumor cells expressing the IL-2 receptor (PMID: 11707818, PMID: 27737881). | |
Temsirolimus | Torisel | CCI-779 | mTORC1 Inhibitor 9 | Torisel (temsirolimus) binds to FKBP-12 and allosterically inhibits mTOR (PMID: 16883305). Torisel (temsirolimus) is FDA approved for advanced renal cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|